Navigation Links
Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinson's Disease at International Neuromodulation Society 10th World Congress
Date:5/26/2011

ble, it may be unable to sustain profitability.
  • At March 31, 2011, the Company had cash and cash equivalents of approximately $5.4 million. Based on its cash flow projections, the Company will need additional financing to carry out its planned business activities and plan of operations after October 31, 2011 and to repay the promissory notes issued in 2010 as of said date. Accordingly, there is substantial doubt as to the Company's ability to continue as a going concern. The Company is currently seeking to raise funds, through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, sufficient to finance its ongoing operations.  The Company does not know whether additional financing will be available when needed, or if available, will be on acceptable or favorable terms to it or its stockholders.
  • The Company will need to conduct future clinical trials for the treatment of Parkinson's disease using the Company's NLX technology. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversely affected and the business may not succeed.
  • There is no assurance as to when, or if, the Company will be able to successfully receive approval from the FDA on its Investigational New Drug Application to commence a Phase 1 clinical trial for the treatment of epilepsy.
  • There is no assurance as to when, or if, the Company will be able to successfully complete the required preclinical testing of its gene therapy for the treatment of depression or Huntington's disease to enable it to file an Investigational New Drug Application with the FDA for permission to begin a Phase 1 clinical trial or that, if filed, such permission will be granted.

  • Other factors and assumptions not identified above could also cause the actual results to differ materially from those set forth in the forward-looking state
    '/>"/>

    SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
    2. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting
    3. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
    4. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
    5. GeoVax Presents Data at AIDS Vaccine 2008 Conference
    6. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
    7. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
    8. Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008
    9. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
    10. Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast
    11. AmeriCares Presents Power of Partnership Award to Baxter
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/4/2015)... , Aug. 4, 2015 Trigemina, Inc., a ... non-narcotic, nasally delivered, analgesic drug products, announced today that ... the position of chief medical officer. Dr. Kori brings ... much of which has been focused in the neuroscience ... add Dr. Kori to our clinical team given his ...
    (Date:8/4/2015)...  Blueprint Medicines (NASDAQ: BPMC ), a leader ... genomically defined diseases, today announced that Jeffrey Albers ... at the 2015 Wedbush PacGrow Healthcare Conference on Tuesday, ... A live webcast of the event will be available ... website at www.blueprintmedicines.com . An archived replay of ...
    (Date:8/4/2015)... ANGELES , Aug. 4, 2015   California ... the recent acquisition of LifeLine Cryogenics, an east coast ... New York tristate area. LifeLine ... and all prepaid contracts will be honored. ... cryogenics services, offering storage of sperm, eggs, embryos, and ...
    (Date:8/3/2015)... Aug. 3, 2015  ArroGen Group, an integrated ... Fingerprint Molecular Identification™ (FMID) technology Aug. 2-8 at ... Sacramento, Calif. ... enable law enforcement agents, district attorneys and government ... suspects. By analyzing chemical residues on ...
    Breaking Biology Technology:Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 2Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 3FamilyCord Announces Acquisition of LifeLine Cryogenics 2ArroGen Previews New Fingerprint Molecular Identification Technology 2
    ... , SEATTLE, July 30 Dendreon Corporation (Nasdaq: DNDN ... a.m. PT; 11:30 a.m. ET to review second quarter 2009 financial results. Access ... Time: 11:30 AM ET /8:30 ... Dial-in: 1-877-548-7903 (domestic) or +1-719-325-4873 (international), ...
    ... LAUSANNE, Switzerland and MEDFORD, Massachussets, ... biopharmaceutical group,of companies with a focus on the ... and MSM Protein Technologies (MSM), a human,antibody drug ... membrane proteins, announce the signature of an exclusive,agreement ...
    ... , , PLEASANTON, Calif., ... (Nasdaq: THOR ), a world leader in device-based ... hearts, and HeartWare International, Inc. (Nasdaq: HTWR ; ... announced today that the United States Federal Trade Commission ("FTC") ...
    Cached Biology Technology:Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET 2Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 2Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 3Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 4U.S. Federal Trade Commission to Challenge Thoratec's Proposed Acquisition of HeartWare International 2U.S. Federal Trade Commission to Challenge Thoratec's Proposed Acquisition of HeartWare International 3U.S. Federal Trade Commission to Challenge Thoratec's Proposed Acquisition of HeartWare International 4
    (Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
    (Date:7/31/2015)... , 31. Juli 2015 Die 10. internationale Konferenz ... BGI veranstaltet und findet vom 22. bis 25. ... , statt. Die Konferenz feiert ... Start 2006 ist die ICG weltweit zu einem ... Sie ist eines der dynamischsten, enthusiastischsten und angenehmsten ...
    (Date:7/27/2015)... LOS ANGELES , July 27, 2015 /PRNewswire/ ... providing evidence- and experience-based clinical improvement solutions, today ... coordination solution is now available on Android smartphones ... at inpatient and post-care organizations can use ZynxCarebook ... the same patient,s condition, streamline care transitions to ...
    Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
    ... cap has been a focal point of recent climate change ... warming than the larger Antarctic ice sheet. Yet while the ... not clear how much this is contributing to rising sea ... such research was defined at a recent workshop organised by ...
    ... professor Karen Warkentin, working at the Smithsonian Tropical ... frog embryos at a very early developmental stage ... reported in the Nov. 7, 2008 issue of ... initial responses to the environment may be critical ...
    ... spread of West Nile virus in North America over the ... the continent, according to an article in the November issue ... little known before its emergence in New York in 1999, ... , West Nile virus has killed hundreds of millions of ...
    Cached Biology News:What is really happening to the Greenland icecap? 2Red-eyed treefrog embryos actively avoid asphyxiation inside their eggs 2
    ...
    Chicken polyclonal to ADI1 ( Abpromise for all tested applications). Antigen: Full length native protein (purified), corresponding to amino acids 1-179 of Human ADI1. Entrez GeneID: 55256 ...
    ABI Plant AFLP Kits • EcoRI-ACA AFLP Amplification Primers...
    Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
    Biology Products: